BioMedNewsBreaks

MondayJul 27, 2026 3:30 pm

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Executive Outlines Lucid-MS Development Strategy and Commercial Growth Plans

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on advancing innovative therapies and technologies, was featured in a recent episode of the BioMedWire Podcast. During the program, Executive Co-Chairman and Co-Founder Anthony Durkacz discussed the company’s strategy for advancing Lucid-MS, its lead drug candidate for multiple sclerosis, as well as the commercial opportunity surrounding its unbuzzd product. Durkacz highlighted Lucid-MS’s goal of addressing mobility damage associated with MS and noted that the company has filed an investigational new drug application for a Phase 2 clinical trial,…

Continue Reading

MondayJul 27, 2026 2:55 pm

BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) Moves Lead Oncology Candidate Toward Future Clinical Studies

Disseminated on behalf of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) is advancing the development of its lead oncology candidate, ONC010, a PNKP inhibitor designed to disrupt cancer cells’ DNA repair mechanisms and potentially address treatment resistance. The company recently advanced kilogram-scale manufacturing of a key precursor used to produce ONC010’s active pharmaceutical ingredient, supporting future formulation development, GMP production and clinical studies. Onco-Innovations also signed a letter of intent with Nanosoft Polymers to advance polymer development, drug delivery optimization and formulation work, while engagements with Nucro-Technics and Avance Clinical support bioanalytical development and clinical…

Continue Reading

MondayJul 27, 2026 2:17 pm

BioMedNewsBreaks — Earth Science Tech Inc. (ETST) Builds on End-to-End Platform Connecting Telemedicine, Pharmacy and Fulfillment

Earth Science Tech (OTC: ETST) recently announced fiscal year 2026 results for the year ended March 31, 2026, highlighting growth across key financial metrics as it continues to operate its diversified holdings model spanning healthcare, pharmaceuticals, telemedicine, real estate and consumer businesses. Revenue increased 8% to $35.7 million, gross profit rose 5% to $25.5 million, net income grew 11% to $3.6 million, and total assets increased 27% to $9 million. CEO Giorgio R. Saumat attributed the results to ETST’s efforts to fully integrate the patient experience across telemedicine to pharmacy to fulfillment. To view the full article, visit https://ibn.fm/mY8eX About Earth Science Tech…

Continue Reading

MondayJul 27, 2026 11:46 am

BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Shareholders Approve Corporate Governance, Financing Measures 

VERAXA Biotech (NASDAQ: VRXA) announced that shareholders overwhelmingly approved all proposals presented at its Extraordinary General Meeting, with more than 99.94% of votes cast in favor and 72.20% of the company's outstanding share capital represented. The approved measures include the introduction of conditional share capital for shareholder options and warrants, implementation of a capital band through Dec. 31, 2030 and an increase in the maximum size of the board of directors from five to seven members. The company said the enhanced corporate and financing framework is intended to support its long-term growth strategy by providing greater flexibility for potential acquisitions, strategic collaborations, investment projects, capital…

Continue Reading

MondayJul 27, 2026 11:31 am

BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration

VERAXA Biotech (NASDAQ: VRXA) announced the advancement of its bispecific antibody-drug conjugate ("bsADC") program, VXA-222, after reaching a key technical milestone in its collaboration with OmniAb (NASDAQ: OABI). The company said OmniAb has successfully completed its discovery work, allowing the program to move into its next phase. VXA-222 is designed to target two tumor antigens with a single molecule using an "AND-gate" approach intended to improve precision in treating solid tumors. Under the collaboration launched in May 2025, OmniAb provided antibody discovery technologies, including its OmniClic(TM) platform, while VERAXA is applying its proprietary linker technology and conjugation expertise to develop and validate the lead bsADC candidate. VERAXA holds exclusive rights to develop and commercialize…

Continue Reading

ThursdayJul 23, 2026 9:30 am

BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Appoints Christoph Erkel as Chief Scientific Officer

VERAXA Biotech (NASDAQ: VRXA) announced the appointment of Christoph Erkel, Ph.D., as chief scientific officer, effective immediately. Erkel, previously vice president of research and development, will lead advancement of the company's proprietary BiTAC(R) platform technologies for the development of cancer therapies targeting solid tumors. He succeeds Rick Austin, Ph.D., who will depart following a transition period. Erkel brings two decades of experience in antibody therapeutics, antibody engineering and preclinical development, including prior leadership roles at MorphoSys AG, where he led immuno-oncology programs focused on T-cell engagers. VERAXA said his experience managing multidisciplinary research programs will support efforts to expand the…

Continue Reading

WednesdayJul 22, 2026 11:57 am

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Publishes Preclinical Data Supporting IV Cancer Therapy

Oncotelic Therapeutics (OTCQB: OTLC) together with Sapu Nano, announced publication of a peer-reviewed study in Biomedicines detailing the preclinical data supporting Sapu003, its intravenous Deciparticle(TM) formulation of everolimus. The publication outlines the program's absorption, distribution, metabolism, excretion ("ADME"), pharmacokinetics, tissue distribution, GLP toxicology and cGMP manufacturing data, supporting the ongoing Phase 1 clinical evaluation of Sapu003 in patients with advanced solid tumors. According to the company, the formulation is designed to overcome pharmacokinetic limitations associated with oral everolimus while preserving the drug's metabolic profile. The published findings also describe reduced gastrointestinal drug exposure compared with oral everolimus, no treatment-related gastric pathology in repeat-dose GLP toxicology studies and…

Continue Reading

TuesdayJul 21, 2026 1:08 pm

BioMedNewsBreaks — VivoSim Labs, Inc. (NASDAQ: VIVS) Announces $4 Million Private Placement 

VivoSim Labs, Inc. (NASDAQ: VIVS) announced it has entered into a securities purchase agreement with a single healthcare-focused institutional investor to raise approximately $4 million in gross proceeds through a private placement of 4,705,883 shares of common stock, or common stock equivalents, and accompanying warrants priced at a combined $0.85 per share. The warrants, which are exercisable following shareholder approval and expire five years after their initial exercise date, carry an exercise price of $0.85 per share. The company also agreed, subject to shareholder approval, to amend certain existing May 2024 warrants by reducing their exercise price from $9.60 to $0.85 per share. The offering is…

Continue Reading

MondayJul 20, 2026 10:41 am

BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Receives Japan Patent Allowance for GelrinC Manufacturing Technology 

Regentis Biomaterials (NYSE American: RGNT) announced that the Japan Patent Office has issued a Notice of Allowance for a patent covering its proprietary organic solvent-free manufacturing process and ready-to-use liquid formulation used in GelrinC(R), the company's regenerative treatment for articular cartilage injuries. Regentis said the allowance expands its global intellectual property portfolio as it advances GelrinC commercialization in Europe, continues enrollment in its pivotal U.S. clinical trial and evaluates expansion into additional international markets. The allowed patent covers proprietary protein-polymer conjugate compositions and manufacturing methods designed to eliminate the use of organic solvents while enabling stable liquid formulations. According to the company, the technology improves manufacturing efficiency, increases production yield, simplifies manufacturing and enhances scalability for commercial…

Continue Reading

MondayJul 20, 2026 9:30 am

BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Receives Regulatory Feedback for BiTAC-TCE Cancer Therapy Platform

VERAXA Biotech (NASDAQ: VRXA) announced it has received Scientific Advice from Germany's Paul-Ehrlich-Institute regarding the underlying biology and proposed non-clinical development plan for its lead proprietary BiTAC-TCE cancer therapy program. The company said the regulatory feedback provides greater clarity on its proposed development strategy and indicates that the agency understands the biological rationale behind its dual-targeting, conditionally active BiTAC-TCE platform, representing an early step in advancing the program toward clinical development. VERAXA also highlighted preclinical data presented at the American Association for Cancer Research Annual Meeting 2026 showing its lead BiTAC-TCE candidate selectively targeted cancer cells expressing both intended targets…

Continue Reading